Quantum Cyber N.V. (QUCY) vs Rallybio (RLYB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 12, 2026.
Summary
Rallybio (RLYB) has outperformed Quantum Cyber N.V. (QUCY) over the past year, gaining 297.5% versus a loss of 34.4%. Rallybio is the larger company by market cap ($89.2 million vs $86.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | QUCY | RLYB |
|---|---|---|
| Share price | $1.03 | $16.79 |
| Market cap | $86.59M | $89.20M |
| 1-day change | -23.70% | -1.35% |
| YTD return | -8.04% | +205.94% |
| 1-year return | -34.39% | +297.49% |
| 5-year return | — | -87.07% |
| P/E ratio (TTM) | — | 2.10 |
| EPS (TTM) | $-2.41 | $8.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.93 | $17.57 |
| 52-week low | $0.30 | $3.67 |
| Distance from 52-week high | -79.11% | -4.46% |
| Analyst consensus | none | — |
| Avg. price target upside | +773.79% | — |
| Average volume | 689.09K | 21.01K |
| Shares outstanding | 84.07M | 5.31M |
| Employees | 10 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLYB has outperformed QUCY by 331.9 percentage points over the past year.
About Quantum Cyber N.V.
QUCY stock →Quantum Cyber N.V. operates as a technology company focused on cybersecurity and quantum computing solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
About Rallybio
RLYB stock →Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
QUCY vs RLYB FAQ
Which is bigger, Quantum Cyber N.V. or Rallybio?
Rallybio (RLYB) is larger, with a market capitalization of $89.20M compared with $86.59M for Quantum Cyber N.V. (QUCY).
Which stock has performed better over the past year, QUCY or RLYB?
RLYB returned +297.49% over the past 12 months, compared with -34.39% for QUCY (price return, excluding dividends). Past performance does not predict future results.
Are Quantum Cyber N.V. and Rallybio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.